{
    "clinical_study": {
        "@rank": "40074", 
        "acronym": "ICC H1", 
        "arm_group": {
            "arm_group_label": "VXA-A1.1", 
            "arm_group_type": "Experimental", 
            "description": "Intestinal Delivery"
        }, 
        "brief_summary": {
            "textblock": "the purpose of the study is to determine the safety and tolerability of VXA-A1.1, an\n      adjuvanted adenoviral based influenza vaccine, when delivery is targeted to the ileum, using\n      a radio controlled capsule.  The secondary objective is to evaluate the immune response\n      (cellular and humoral) of two doses of VXA-A1.1 oral vaccine."
        }, 
        "brief_title": "Immunogenicity of Seasonal Influenza by Delivery Directly to Ileum", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Seasonal Influenza", 
        "condition_browse": {
            "mesh_term": "Influenza, Human"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Able and willing to complete informed consent\n\n          -  Healthy, as established by medical history, physical exam, and laboratory assessments\n\n          -  Has normal bowel movements\n\n          -  Willing to abstain from caffeine and xanthine containing substances for 24 hours\n             before procedure until after discharge\n\n        Exclusion Criteria:\n\n          -  Not able to donate up to 550 ml of blood over several months\n\n          -  Exposure to an investigational drug or vaccine 8 weeks prior to study\n\n          -  Abnormal ECG findings\n\n          -  History of irritable bowl or any other inflammatory gastrointestinal disorder\n\n          -  Any individual with increased risk for bowl obstruction\n\n          -  Radiation exposure above target values 50 mSv within the past 30 days or a cumulative\n             dose above 150 mSV in the past 12 months\n\n          -  History of substance abuse\n\n          -  Subject unwilling to use an approved method of contraception during study and for 2\n             months after study\n\n          -  Positive for HCV, HIV, or HBV\n\n          -  Presence of implantable device that is sensitive to radio frequencies ( e.g.\n             pacemakers)\n\n          -  History of autoimmune disorder, or an immunosuppressive disorder\n\n          -  Stool sample with occult blood at baseline\n\n          -  Any other medical, psychiatric, social condition, or occupation, in the judgement of\n             the investigator is a contraindication to the compliance of the protocol or informed\n             consent"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "49 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01761123", 
            "org_study_id": "VXA02-002"
        }, 
        "intervention": {
            "arm_group_label": "VXA-A1.1", 
            "intervention_name": "VXA-A1.1", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Prevention of Influenza", 
        "lastchanged_date": "January 28, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Lexington", 
                    "country": "United States", 
                    "state": "Kentucky"
                }, 
                "name": "Scintipharma"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open Label Phase I Substudy to Evaluate the Safety and Ability to Enhance Immunogenicity of VXA-A1.1 by Delivery Directly to the Ileum Using the InteliSite Companion Capsule in Healthy Adult Males", 
        "overall_official": [
            {
                "affiliation": "Scintipharma", 
                "last_name": "Walter Doll, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Vaxart, Inc.", 
                "last_name": "David Liebowitz, MD, PhD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Frequency and magnitude of adverse events", 
            "measure": "Safety", 
            "safety_issue": "Yes", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01761123"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Antibody and T cell responses to HA", 
            "measure": "Immunogenicity", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "source": "Vaxart", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Vaxart", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}